<- Go Home
Eterna Therapeutics Inc.
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Market Cap
$26.4M
Volume
19.0K
Cash and Equivalents
$4.3M
EBITDA
-$20.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$436.0K
Profit Margin
72.91%
52 Week High
$2.63
52 Week Low
$0.49
Dividend
N/A
Price / Book Value
-0.06
Price / Earnings
-0.06
Price / Tangible Book Value
-0.06
Enterprise Value
$59.8M
Enterprise Value / EBITDA
-4.52
Operating Income
-$20.3M
Return on Equity
214.83%
Return on Assets
-42.35
Cash and Short Term Investments
$4.3M
Debt
$37.7M
Equity
-$45.4M
Revenue
$598.0K
Unlevered FCF
-$11.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium